secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264658
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M
--------------------------------------------------------------------------------

- Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.
- 1,043 patient start forms and 764 active patients on VYKAT XR as of Sept 30, 2025; 494 unique prescribers and over 132M lives covered since March approval.
- Cash and securities at $556.1M, including $230M gross proceeds from July common stock offering; operating cash flow of $43.5M in Q3.
- Sequential product revenue more than doubled from $32.7M in Q2 2025; R&D expense fell to $8.4M from $30.1M, and SG&A to $33.8M from $49.2M.
- Appointed Mark W. Hahn to Board of Directors and Audit Committee; contingent consideration liability for Essentialis earnout estimated at $19.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525264658/0001193125-25-264658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525264658/d58763d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer